Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
"We look forward to feedback from the DMC following their review of the trial data," stated Myron Holubiak, President and Chief Executive Officer of Citius.
- "We look forward to feedback from the DMC following their review of the trial data," stated Myron Holubiak, President and Chief Executive Officer of Citius.
- The first two interim analyses were conducted by the DMC in 2019 and 2020, respectively.
- The next interim analysis meeting of the DMC will be held on June 29, 2021.
- At that time, the DMC will review unblinded study data and subsequently provide written recommendations to Citius within five business days.